Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance
Revenue in Q4 2023 increased 28%. New Products(i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products(ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance.
2023 年第四季度的收入增长了 28%。在Mounjaro和Zepbound的带动下，新产品（i）收入在2023年第四季度增长了21.9亿美元，达到24.9亿美元。增长产品（ii）收入在2023年第四季度增长了9％，达到52.7亿美元，由Verzenio和Jardiance领先。
Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma under the Accelerated Approval Program. Additional progress included positive results from SYNERGY-NASH, a Phase 2 study of tirzepatide in adults with nonalcoholic steatohepatitis (NASH), also known as metabolic dysfunction-associated steatohepatitis (MASH).
管道进展包括美国食品药品管理局批准Zepbound用于肥胖或超重并发体重相关合并症的成年人，以及根据加速批准计划批准Jaypirca用于慢性淋巴细胞白血病或小淋巴细胞淋巴瘤。其他进展包括SYNERGY-NASH的积极结果，这是一项针对非酒精性脂肪肝炎（NASH）（也称为代谢功能障碍相关性脂肪性肝炎（MASH）成人的替塞帕肽的2期研究。
Business development activity included the completed acquisitions of POINT Biopharma Global Inc. and Mablink Biosciences SAS.
业务发展活动包括完成对POINT Biopharma Global Inc.和Mablink Biosciences SAS的收购。
Q4 2023 EPS increased 13% to $2.42 on a reported basis and increased 19% to $2.49 on a non-GAAP basis, both inclusive of $0.62 of acquired IPR&D charges.
根据报告，2023年第四季度每股收益增长了13％，至2.42美元，按非公认会计准则计算，增长了19％，至2.49美元，均包括收购的0.62美元的知识产权和开发费用。
2024 guidance issued with revenue in the range of $40.4 billion to $41.6 billion, EPS in the range of $11.80 to $12.30 and non-GAAP EPS in the range of $12.20 to $12.70.
发布的2024年指引显示，收入在404亿美元至416亿美元之间，每股收益在11.80美元至12.30美元之间，非公认会计准则每股收益在12.20美元至12.70美元之间。
